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ABSTRACT
The anti-cancer agent CBP501 binds to calmodulin (CaM). Recent studies showed 
that migration and metastasis are inhibited by several CaM antagonists. However, 
there is no available evidence that CBP501 has similar effects. Here we found that 
CBP501 inhibits migration of non-small cell lung cancer (NSCLC) cells in vitro, even 
in the presence of migration inducing factors such as WNT, IL-6, and several growth 
factors. CBP501 also inhibited epidermal growth factor (EGF) enhanced invasion and 
the epithelial-to-mesenchymal transition (EMT), and this inhibition was accompanied 
by (i) suppression of Akt and ERK1/2 phosphorylation, and (ii) suppression of 
expression of transcription factor Zeb1 and the mesenchymal marker Vimentin. 
A pull down analysis performed using sepharose-immobilized CaM showed that 
CBP501 blocks the interaction between CaM and KRas. Furthermore, EGF induced Akt 
activation and cell migration was effectively suppressed by KRas down-regulation 
in NSCLC cells. Stable knockdown of KRas also made cells insensitive to CBP501’s 
inhibition of growth factor-induced migration. Taken together, these results indicate 
that CBP501 inhibits binding of CaM with KRas and thereby suppresses the PI3K/AKT 
pathway, migration, invasion and EMT. These findings have identified a previously 
unrecognized effect of CBP501 on downstream KRas signaling mechanisms involving 
EMT and invasion, and provide support for the further clinical development of this 
agent.
INTRODUCTION
Metastasis leads to death in about 90% of cancer 
patients [1]; accordingly, inhibition of cancer cell mobility 
would be of therapeutic benefit. Cell migration, invasion 
and EMT are the fundamental processes associated 
with cancer metastasis [2]. EMT contributes to cancer 
progression and is evoked during tumor invasion and 
metastasis [2-4]. EMT can be triggered by a variety of 
different molecules such as TGFβ, WNTs, IL-6, Notch, 
EGF, HGF, FGF, and HIF, and many diverse pathways 
have been implicated [2-4]. EMT is experimentally 
characterized by a decrease in the epithelial-state protein, 
E-cadherin, and increases of the mesenchymal-state 
proteins, vimentin [5].
Vimentin, one of the markers of EMT, is a regulator 
of cellular motility [6]. This was published in 2011, 
vimentin has gained attention as a potential molecular 
target for cancer therapy [7]. Overexpression of vimentin 
is associated with an increased capacity for cell migration 
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and tissue invasion. Overexpression of vimentin was 
found to be an independent prognosticator for poor 
survival in resected NSCLC patients [8]. Others showed 
vimentin to be an Akt target, mediating cell motility and 
tissue invasion through its pathway [9].
The PI3K/Akt pathway is intimately connected to 
the migration of motile cells, including metastatic cancer 
cells [10]. It is possible that CaM-directed inhibitors 
exert their inhibition of cell migration via the PI3K/
Akt pathway. W7, a CaM-directed inhibitor, suppresses 
EGF-induced Akt activation [11, 12]. Trifluoperazine, 
another CaM inhibitor, attenuates cancer cell invasion 
without cytotoxicity by suppressing Akt, and is a potential 
candidate for preventing cancer metastasis [13]. Thus, 
some CaM inhibitors might possibly serve as metastasis 
suppressors.
The Ras protein family (HRas, NRas, KRas4A and 
KRas4B) controls many cellular processes such as cell 
proliferation, transformation, differentiation, metastasis 
and apoptosis. Nussinov R et al. [14] proposed that 
CaM binding to KRas4B promotes cell proliferation and 
migration via the MAPK and Akt pathways. Wolfman 
et al. [15] proposed that cell migration is closely related 
to growth factor-dependent Akt activation and KRas/
CaM interaction. In addition, McCormick et al. [16-20] 
proposed that blocking the specific interaction between 
KRas and CaM can be a novel approach to target KRas 
signaling in cancer therapy.
CBP501 is an anti-cancer agent that increases the 
sensitivity of tumor cells to platinum by CaM inhibition 
[21]. CaM inhibitors act by enhancing the antineoplastic 
effects of cisplatin [22]. Relative to other CaM inhibitors, 
CBP501 shows higher in vitro codrug activity with 
platinum [21]. Although several reports show that CaM 
inhibitors suppress cell migration and invasion, it was 
unknown whether CBP501 had such an inhibitory effects. 
Here, we positively established CBP501’s effects on 
cell migration, invasion and EMT and identified that the 
mechanism of CBP501’s inhibition of EGF-mediated cell 
migration and tissue invasion entailed reduced PI3K/Akt 
activation that ultimately stemmed from inhibition of 
KRas/CaM binding.
RESULTS
CBP501 inhibits NSCLC cell migration and 
invasion in vitro
Two mesenchymal-like NSCLC cell lines A549 
(KRas mutation at codon 12) and H1299 (wild-type KRas 
and mutated NRas) were employed.
The effect of CBP501 on migration was examined 
by a cell migration assay. As shown in Figure 1A 
and 1B left panels, 1 μM CBP501 inhibited 42% of 
total cell migration in A549 cells and 70% in H1299 
cells. CBP501 also inhibited wound closure of A549 
and H1299 in a scratch assay (Supplementary Figure 
1A and 1B).
The effects of CBP501 on cell invasion were 
assessed by an in vitro matrigel cell invasion assay 
and a 3-D spheroid cell invasion assay. H1299 cells 
were found to be highly invasive whereas A549 were 
relatively lowly invasive (Supplementary Figure 2A 
and 2B). An in vitro invasion assay using BD BioCoat 
Matrigel invasion chamber showed that 1 μM CBP501 
inhibited invasion by 32% in A549 and by 49% in 
H1299 (Figure 1A and 1B right panels). A 3-D spheroid 
cell invasion assay was performed to further investigate 
the effect of CBP501 on cell invasion in H1299 
cells. The cells were grown as spheroids surrounded 
by an extracellular matrix (ECM) before inducing 
cell invasion by adding serum. Consistent with the 
transwell assay, CBP501 reduced the extent of spindle-
like protrusions in the invasion matrix (Figure 1C). 
Analysis of these measurements at varying dose-levels 
indicated that CBP501 attenuates both cell migration 
and invasion in a dose-dependent manner.
To confirm that the inhibition of cell migration 
and invasion by CBP501 did not arise from cytotoxicity 
of CBP501, A549 and H1299 cells were analyzed for 
potential toxic effects in the presence of increasing 
concentrations of CBP501 using a WST8 cell viability 
assay. In these tests, cell viability was not affected by 
CBP501 at the 5 μM and 72 h (Supplementary Figure 3A 
and 3B). W7 and calmidazolium chloride (CMZ) had no 
effect on cell viability at concentrations up to 20 μM and 
5 μM, respectively (Supplementary Figure 3C and 3D).
The CaM antagonists, trifluoperazine and 
ophiobolin A, had been found to prevent cell migration 
and invasion [13, 23]. Here, we confirmed that CaM 
antagonists (W7 and CMZ) also prevented cell migration 
(Supplementary Figure 4A; A549 and 4B; H1299) and 
prevented the formation of spindle-like protrusions in the 
invasion matrix (Supplementary Figure 5).
EMT-inducing factors could not reverse 
CBP501-induced suppression of migration
EMT induction can be triggered by a variety of factors 
including TGFβ, WNTs, IL-6, Notch, EGF, HGF, FGF, HIF, 
and many others [3]. A chemotaxis assay was performed 
with only H1299 cells because A549 did not survive for 
the required 48 h to 72 h in serum-free medium. CBP501-
induced suppression of migration could not be reversed by 
any of the known EMT-inducers or inducer mixtures as 
shown in Figure 2A (WNT mixture, IL-6 and Growth factor 
mixture), Figure 2B (WNT3a, WNT5a, EGF, HGF, IGF-I 
and FGF), Figure 2C (WNT5a and EGF with CBP501 and 
AG1478) and Figure 2D (WNT5a and IGF-I with CBP501 
and PQ401). In these experiments, EMT-inducing factors 
were added to the lower chambers of the migration test 
wells. Similar CBP501-induced suppression of migration 
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was obtained with added TGFβ (Supplementary Figure 
6A). AG1478, an EGFR inhibitor, specifically inhibited 
EGF-dependent migration but could not inhibit WNT5a-
dependent migration. However, CBP501 inhibited cell 
Figure 1: CBP501 prevents cell migration and invasion in A549 and H1299 cell lines. Serum-starved A549 (A, left panel) or 
H1299 (B, left panel) cells were treated with CBP501 (0.25, 0.5 or 1 μM) for 24 h using a transwell assay. Serum-starved A549 (A, right 
panel) or H1299 (B, right panel) cells were treated with CBP501 (1 μM) for 48 h using matrigel invasion chamber. Cell migration and 
invasion %ages (above) were calculated from sample eluted from the membrane (n = 3). Photomicrographs of the observed cell migration 
(below). (C) Quantification of H1299 cell invasion in spheroid invasion assays. Cells were aggregated into spheroids and then induced to 
invade the surrounding matrix for 11 days. The total area of the invading spheroid was calculated with Image-J software and taken to be 
a measure of cell invasion (n = 3). Red signal threshold was set to capture the total structure. Scale bar is 500 μm. Data, the mean ± SD; * 
and **, P < 0.05 and P < 0.005, respectively.
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Figure 2: CBP501 prevents cell migration of H1299 cells by various EMT inducing factors. (A) H1299 cells were treated 
over 72 h with CBP501(1 μM) in combination with various human (recombinant) migration-inducing factors; WNT mix (100 ng/mL WNT-
3a and 100 ng/mL WNT-5a), 100 ng/mL IL-6, Growth Factor mix (GF mix; 500 ng/mL EGF, 50 ng/mL HGF, 200 ng/mL IGF-I and 100 
ng/mL FGF). (B) (Left) H1299 cells were treated with WNT-3a or WNT-5a in combination with CBP501 for 72 h. (Right) H1299 cells 
were treated with EGF, HGF, IGF-I or FGF in combination with CBP501 for 72 h. (C) H1299 cells were treated with WNT-5a or EGF in 
combination with CBP501 or AG1478 for 72 h. (D) H1299 cells were treated with WNT-5a or IGF-I in combination with CBP501 or PQ401 
for 72 h. Scale bar is 500 μm. Data, the mean ± SD; * and **, P < 0.05 and P < 0.005, respectively.
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migration in the presence of both WNT5a and EGF (Figure 
2C). Similar results were obtained for an IGF-I inhibitor, 
PQ401 (Figure 2D). These findings suggest that CBP501 
can inhibit cell migration even in the presence of a broad 
range of EMT-inducing factors.
CBP501 reduces EMT-related proteins through 
inhibition of Akt pathway
EGF is known to induce EMT by promoting 
E-cadherin endocytosis [24], but it can also induce the 
expression of Zeb1, repressing E-cadherin transcription 
among other targets. Here we focused on the EGF-
stimulated cell motility.
Western blot analysis demonstrated that expression 
of E-cadherin protein was significantly down-regulated 
by EGF stimulation, and that expression of vimentin and 
Zeb1 proteins was up-regulated in the EGF-treated cells 
compared to the untreated cells (Figure 3A). In contrast, 
1 μM CBP501 reduced expression of EGF-induced Zeb1 
and vimentin (Figure 3A). It is interesting to note that 
CBP501 might have induced vimentin proteolysis (Figure 
3A, left panel) (FL, full length; CF, cleaved fragment). 
Similar effects were also seen upon treatment of A549 
cells with CBP501 and TGFβ (Supplementary Figure 6B).
The PI3K/Akt pathway regulates cell migration and 
EMT [9, 10, 25]. Other CaM antagonists inhibit growth 
factor-induced migration and Akt activation [11, 12, 15]. 
BAPTA-AM, a cell-permeant Ca2+ chelator which has 
CBP501-like activity, was reported to suppress EGF-
induced vimentin protein expression [26]. Moreover, Akt 
inhibition is known to induce caspase dependent vimentin 
proteolysis [9]. We therefore tested whether CBP501 
represses EGF-induced Akt activation in A549 cells. 
As shown in Figure 3B, CBP501 significantly blocked 
the EGF-dependent Akt activation (pAkt, pERK1/2) 
in A549 cells. Akt IV inhibitor was used as a positive 
control of Akt inhibition. Similar effects were also seen 
in H1299 cells (data not shown). To further investigate 
the effect of CBP501 in EGF-dependent cell invasion, 
we performed 3-D spheroid cell invasion assay in H1299 
cells. The spheroids were formed by ECM and cell 
invasion was induced by the addition of EGF. CBP501 
reduced the formation of spindle-like protrusions upon 
EGF stimulation of cells in the invasion matrix (Figure 
3C). These findings suggest that CBP501 inhibits EMT 
induction via the PI3K/Akt pathway.
Knockdown of KRas by shRNA impairs the 
effects of CBP501 on inhibition of cell migration
The Ras pathway is a major driver in lung 
adenocarcinoma [19]. KRas has long been a target for 
anti-cancer drug development, although many earlier 
strategies, including those targeting farnesyltransferase, 
have been disappointing. It was speculated in a review 
that a binding of CaM to KRas4B activates the PI3K/Akt 
pathway and that could enhance cell migration [14]. To 
confirm whether KRas relates to cell migration, we created 
a stable cell line exhibiting KRas knockdown by lentiviral-
mediated shRNA interference in A549 and H1299 cells. 
The levels of KRas expression was analyzed by western 
blot analysis (Figure 4A).
KRas–deficient cells are reported to show decreased 
EGF-dependent Akt activation and cell migration [15, 27]. 
Concordantly, KRas-knockdown cells showed attenuated 
phosphorylation of Akt by EGF stimulation (Figure 4B). 
KRas-knockdown cells showed reduced migration with 
or without CBP501 compared with control cells of both 
the A549 and H1299 cell lines (Figure 4C). Interestingly, 
CBP501 did not suppress cell migration when the 
migration was induced by the mixture of EGF and IGF-I 
(Figure 4D) in the KRas-knockdown cell lines. These 
findings suggest that KRas contributes to the migration of 
NSCLC cells and is also at least partially involved in the 
inhibitory effect of CBP501 on cell migration.
CBP501 inhibits CaM and KRas binding in vitro
Recent evidence suggests that Ca2+-CaM 
selectively modulates KRas4B signaling [14, 28-30]. 
Unlike other isoforms, KRas4B can interact with CaM 
in a Ca2+-dependent manner [15, 31-33]. McCormick 
et al. recently proposed that blocking specific 
interactions between CaM and KRas may provide a 
novel approach to target KRas signaling in cancer [16-
20]. Correspondingly, the highly potent CaM inhibitor 
ophiobolin A interferes with KRas activity by binding 
to and inhibiting CaM directly, as observed through 
reduced mammosphere formation [34]. The interaction 
between CaM and KRas was reported to regulate growth 
factor-dependent Akt activation and cell migration [15]. 
To investigate whether CBP501 inhibits CaM and KRas 
binding, we analyzed this interaction in vitro using CaM-
sepharose pull down assays with H1299 cell lysate. KRas 
was able to bind to CaM-sepharose in the presence of 
Ca2+, and the binding could be suppressed by added 
CBP501 and EGTA (Figure 5A). As shown in Figure 
5B and 5C, CBP501, Ophiobolin A (OBA) and CMZ 
specifically suppressed CaM/KRas binding, but did not 
inhibit interaction of CaM with either IQGAP1 [35] or 
p68 RNA helicase [36], two other CaM-binding proteins. 
CaM/KRas binding inhibition by CBP501 was also seen 
with A549 cell lysate (Figure 5D). These results using 
three different CaM antagonists suggest that CBP501 is 
quite specific at suppressing CaM/KRas binding.
DISCUSSION
In the present study, we investigated mechanisms by 
which CBP501 inhibits cell migration, invasion and EMT. 
The seminal findings of this work are: (i) CBP501 inhibits 
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NSCLC cell migration and invasion in vitro; (ii) many 
EMT-inducing factors can not reverse the suppression of 
migration by CBP501; (iii) CBP501 reduces expression 
of EMT-induced proteins with inhibition of the Akt 
phosphorylation;(iv) knockdown of KRas by shRNA 
negates inhibition of migration by CBP501; and (v) 
CBP501 inhibits the formation of a complex between CaM 
and KRas. These findings indicate that CBP501 inhibits 
Figure 3: CBP501 attenuates EGF-dependent EMT via PI3K/Akt pathway. (A) A549 cells were treated with or without EGF 
(50 or 100 ng/mL) in combination with CBP501 (1 or 5 μM) for 72 h. Cell lysates were analyzed by western blot assay with antibodies to 
E-cadherin, Vimentin, Zeb1, and β-actin. The measured band density was normalized relative to that of the control sample, with the control 
value set to 1. β-actin was used as a loading control. The results are the average relative intensity of three replicate blots. FL, full length; 
CF, cleaved fragment. (B) A549 cells were serum-starved for 1 day and then pretreated with CBP501 (1 μM) for 3 h before stimulating with 
EGF. The cells were treated with EGF (100 ng/ml) for 0-60 min. Cell lysates were analyzed by western blot assay (n = 3) with antibodies 
to pAkt, Akt, pERK1/2, ERK1/2, pSTAT3, STAT3 and β-actin. (C) Quantification of H1299 cell invasion by EGF stimulation in spheroid 
invasion assay. Cells were aggregated into spheroids and then induced to invade the surrounding matrix for 7 days with or without EGF 
(500 ng/mL) stimulation. The total area of each invading spheroid was calculated with Image-J software and taken to be a measure of cell 
invasion (n = 3). Red signal threshold was set to capture the total structure. Scale bar is 500 μm. Data, the mean ± SD; * and **, P < 0.05 
and P < 0.005, respectively.
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Figure 4: KRas knockdown cells attenuate inhibition of cell migration by CBP501. (A) Stable silencing of KRas in A549 
and H1299 cells was assessed by comparing KRas expression in cell lysates from cells transduced with a control shRNA (shCont) or with 
KRas shRNA (shKRas) lentiviruses using a western blot assay. (B) Serum-starved A549 shCont and shKRas cells were treated with EGF 
(100 ng/mL) for 0-60 min. Cell lysates were analyzed by western blot assay (n = 3) with antibodies to pAkt, pERK1/2 and β-actin. (C) 
Serum-starved A549 or H1299 cells were treated with CBP501 for 24 h using transwell assay (n = 3). (D) Serum-starved H1299-shCont 
or H1299-shKRas cells were treated with EGF (500 ng/mL) and IGF-I (200 ng/mL) in combination with CBP501 for 72 h using transwell 
assay (n = 3). Data, the mean ± SD; * and **, P < 0.05 and P < 0.005, respectively; n.s., nonsignificant.
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Figure 5: CBP501 inhibits KRas/CaM interaction. (A) Cellular lysates (1 mL) from H1299 cells were incubated with CaM-
sepharose together with CBP501 (2 μM) or EGTA (1 mM) in the presence of Ca2+ for 2 h as indicated in Materials and Methods. The 
presence of KRas and β-actin were analyzed by western blot assay using specific antibodies. (B) Cellular lysates (1 mL) from H1299 cells 
were incubated with CaM-sepharose (CaM-seph) or with Plain (Seph) beads together with CBP501 (2 μM) or OBA (2 μM) in the presence 
of Ca2+ as indicated in Materials and Methods. Cellular lysates (1 mL) from H1299 cells (C) and A549 cells (D) were incubated with CaM-
sepharose (CaM-seph) or with Plain (Seph) beads together with CBP501 (2 μM), W7 (20 μM) or CMZ (5 μM) in the presence of Ca2+ as 
indicated in Materials and Methods. Cell lysates were analyzed by western blot assay with antibodies to KRas, IQGAP1, p68 and β-actin. 
The results are the average relative intensity of three replicate blots.
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EGF-dependent cell migration by inhibiting the formation 
of CaM/KRas complex and suppressing Akt activation.
Since CaM is involved in many cellular phenomena, 
it requires much effort to clarify the complete function 
of any CaM-directed inhibitor [37]. Given CBP501’s 
observed anti-CaM activity, CBP501 might conceivably 
have affected CaM’s action by two avenues: (a) by 
inhibiting CaM-dependent signaling pathways that 
control cell migration; (b) by inhibiting CaM-dependent 
cytoskeletal processes including actin filament formation 
and the action of microtubule motor proteins such as 
dynein and kinesin (Figure 6). In the current work, we 
clarified that the CaM-directed inhibitor CBP501 regulates 
EGF-dependent cell migration by inhibiting CaM/KRas 
binding and through the Akt pathway (Figure 6). CBP501 
can inhibit cell migration in the presence of a broad-
range of EMT-inducing factors other than EGF. Future 
analysis is necessary to investigate the basis for this broad 
inhibition of cell migration caused by mechanisms other 
than EGF stimulation.
EMT is regulated by several signaling pathways 
that interact to produce a full range of EMT responses 
[38]. EMT induction is increased through crosstalk and 
cooperation between these distinct pathways. WNT 
signaling can promote EMT by inhibiting glycogen 
synthase kinase-3β (GSK3β) to stabilize β-catenin. The 
CaM antagonist trifluoperazine suppresses tumor spheroid 
formation and down-regulates WNT/β-catenin signaling 
[39]. Interleukin-6 (IL-6) is a cytokine present in tumor 
microenvironment and can promote EMT through 
enhancing STAT3, MAPK and Akt signaling [40].
Ca2+ and CaM have been reported to participate 
in cell migration [41]. Ca2+-CaM was found to inhibit 
the binding of F-actin and Cdc42 to IQGAP1 [42, 43]. 
IQGAP1 acts as a scaffold protein that couples cell 
signaling to processes involving the actin and microtubule 
cytoskeletons during cell migration [44]. Binding between 
Ca2+-CaM and IQGAP1 was found to attenuate cell 
migration [45]. Interaction between CaM and IQGAP1 
was also found to reduce induction of ERK activity by 
EGF [46]. As shown in Figure 3B, EGF-induced ERK 
activity was reduced by CBP501. Thus, CBP501 may 
inhibit not only the PI3K/Akt pathway, but also the 
Raf/MEK/ERK pathway. Cdc42 is another possible site 
of CaM action that may be affected by CBP501. It is a 
member of the Rho family of small GTPases and has been 
shown to induce filopodia formation, a process entailing 
cytoskeleton organization and consequently possibly 
affecting cell migration [42]. Initial results from the CaM-
sepharose pull-down experiments indicated that CBP501 
might also possibly enhance CaM/Cdc42 binding (data 
not shown). A further possible site of CaM action that 
might have been affected by CBP501 was the interaction 
between Ca2+-CaM and p68 RNA helicase, which was 
reported to promote cell migration and metastasis [36]. 
The p68 interacts with microtubules in the presence of 
Ca2+-CaM and can function as a microtubule motor. The 
IQ-like motif peptide of p68 interrupts the interaction 
between p68 and Ca2+-CaM and inhibits cell migration 
[36]. Since CBP501 did not inhibit the binding between 
CaM and p68, CBP501 is unlikely to be related to this 
mechanism (Figure 5C and 5D). Further analysis is 
necessary for these migration mechanisms.
Figure 6: Schematic representation that summarizes the proposed mechanism of action of CBP501 as described in 
the text. CBP501 interacts with CaM, blocking its observed (or potential) interactions with KRas, GPCRs or IL-6R, thereby affecting 
a variety of pathways related to cell migration, invasion and EMT. GFRs, growth factor receptors; GPCRs, G protein-coupled receptors; 
IL-6R, interleukin-6 receptor.
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The PI3K/Akt pathway regulates cell migration 
[10]. We tested whether Akt inhibitor Akt IV inhibits 
cell invasion with transwell. Akt IV inhibited invasion 
both A549 and H1299 cells (Supplementary Figure 
7A). CaM directly also binds to Akt and modulates Akt 
translocation to the plasma membrane [47, 48]. We tested 
whether CBP501 inhibits binding of Akt/CaM using pull 
down assay. CBP501 did not inhibit Akt/CaM interaction 
(Supplementary Figure 7B). Furthermore, CaM is an 
integral component of a K-Ras4B/PI3Kɑ ternary complex 
[49]. CBP501 may interfere with the trimer formation.
Given that the interaction between KRas and 
CaM was found to be significant here, there are three 
different regions in the KRas protein that are known to 
be important for its interaction with CaM [31]. These are 
the hypervariable region, the ɑ-helix between amino acids 
151 and 166, and the Switch II region [31, 33]. Further 
investigation is needed to identify whether there is direct 
interaction of CBP501 with any of these sites on KRas. 
The selective inhibition of KRas-CaM binding by CBP501 
may instead result from a stable, KRas-incompatible 
conformer assumed by CaM in a stable CaM-CBP501 
complex or from CBP501’s blocking of CaM’s usual sites 
of interaction with KRas in such a CaM-CBP501 complex.
In conclusion, this study provides the first evidence 
that CBP501 can inhibit lung cancer cell migration, 
invasion and EMT. In the case of EGF induced migration, 
invasion and EMT it was shown that CBP501 inhibited 
EGF-induced PI3K/Akt pathway via suppression of 
CaM/KRas binding. CBP501 provides a novel approach 
to target KRas signaling in cancer in addition to the 
known anti-cancer action which is the augmentation of 
cytotoxicity of platinum agents to tumor cells [21].
MATERIALS AND METHODS
Cell lines and reagents
Human NSCLC cell lines, A549 (KRas mutant) and 
H1299 (KRas wild-type) were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). Cell lines 
were authenticated by short tandem repeat analysis. Cell 
lines were initially grown and low passage stocks were 
cryopreserved in liquid nitrogen. Cells were replaced by 
frozen stocks after 3 months of continuous culture. A549 
cells were cultured in Ham’s F-12K (Kaighn’s) medium 
(Gibco; Thermo Fisher Scientific Inc., Waltham, MA) 
containing 10% fetal bovine serum (FBS) (Gibco) and 1% 
penicillin/streptomycin (PS) (Gibco). H1299 cells were 
cultured in RPMI1640 medium (Sigma-Aldrich, St. Louis, 
MO) containing 10% FBS, 1% PS. Cells were grown at 
37°C in humidified atmosphere consisting of 5% CO2 and 
95% air. CBP501 was manufactured by Lonza (Braine-
l’Alleud, Belgium). Akt inhibitor IV, EGFR inhibitor 
AG1478 and IGF-IR inhibitor PQ401 were purchased 
from Millipore (Bellerica, MA). Ophiobolin A was 
purchased from Enzo life science (Lausen, Switzerland). 
CaM inhibitor, W7 and Calmidazolium chloride were 
purchased from Sigma-Aldrich. Recombinant human 
WNT-3a, WNT-5a, IL-6, EGF, HGF, IGF-I and FGF were 
purchased from R & D systems (Minneapolis, MN).
In vitro transwell migration assay
Cell migration assays were performed in 24-well 
plates with 8 μm pore sized transwell chambers (Corning, 
#3422, Kennebunk, ME). The cells were serum-starved 
overnight in serum-free medium (0.1% BSA). A total 
1-5 x 104 cells in serum-free medium (0.1% BSA) were 
added to the upper chamber. RPMI1640 (2% FBS) or 
F12K (10% FBS) were added to the lower chamber. 
A549 and H1299 cells were cultured for 24 h to observe 
migration. The migrated cells were stained with crystal 
violet (BD biosciences, San Jose, CA) for 15 min at room 
temperature. The crystal violet stain was then removed 
from the chambers, and cells were washed thrice with 
distilled water (dH2O). Cells on the upper chamber of 
the membrane were scraped off using a cotton swab. 
The experiment was performed in triplicates for all 
conditions described. Cell migrations were captured using 
an Olympus CKX41 microscope (Olympus Optical Co., 
Hamburg, Germany) via Moticam 580 digital camera 
(Motic, Hong-Kong, China) at 40-fold magnification. 
Crystal violet was then eluted with extraction buffer (2.5% 
methanol, 2.5% Isopropanol, 30% ethanol and 0.5% acetic 
acid) in dH2O and the eluted samples were transferred to a 
96-well plate. The migrated stained cells were quantified 
by colorimetric measurement at 550 nm. The absorbance 
at 550 nm (OD
550
) was measured using a Sunrise basic 
microplate reader (Tecan Austria GmbH), in accordance 
with the manufacturer’s instructions.
In vitro transwell matrigel invasion assay
Cell invasion assays were performed with a 
BioCoat Matrigel Invasion Chamber (Corning, Bedford, 
MA). The cells were serum-starved overnight in serum-
free medium (0.1% BSA). A total of 2 x 104 cells in 
serum-free medium (0.1% BSA) were added to the top 
invasion chambers of 24-well transwell plates containing 
a cell culture insert with an 8 μm pore size. RPMI1640 
(2% FBS) or F12K (10% FBS) were added to the lower 
chamber. A549 and H1299 cells were cultured in the 
culture insert to observe the invasion for 48 h. The 
procedure after the crystal violet staining is the same as 
for the cell migration assay.
3-D Spheroid cell invasion assay
The invasive ability of the H1299 cells 
was investigated using the Cultrex 96 Well 3-D 
Spheroid BME Cell Invasion Assay according to 
the manufacturer’s instructions (Trevigen, Inc., 
Oncotarget74016www.impactjournals.com/oncotarget
Gaithersburg, MD). Briefly, 250 cells were resuspended 
for spheroid formation in ECM solution and gently 
pelleted in a 96 well round bottom spheroid formation 
plate. After 3 days, spheroids were imaged. To induce 
invasion, the invasion matrix and a serum-containing 
medium were added to each well. Cells invaded the 
surrounding matrix for 7 to 11 days. Images were 
captured using an Olympus CKX41 microscope via 
Moticam 580 digital camera at 40-fold magnification. 
The area of each cell mass (pre- and post-invasion) 
was measured using Image-J software (NIH, Bethesda, 
MD). The difference between the pre- and post-invasion 
areas was used a measure of cell invasion.
Chemotaxis assay
The chemotaxis assay was performed using 
transwell chambers. The cells were serum-starved 
overnight in serum-free medium (0.1% BSA). Briefly, 
RPMI1640 (0.5% FBS) containing the chemoattractant 
(eg, EGF, IGF-I, etc.) was added to the lower chamber. A 
total of 1 × 104 cells in serum-free medium (0.1% BSA) 
were added to the upper chamber. Then, the chamber 
was incubated at 37°C for 72 h. The procedure after 
the crystal violet staining is the same as for the cell 
migration assay.
Cell extracts and Western blot assay
To prepare extracts from the cell culture, cells 
were washed with PBS and resuspended in lysis 
buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 0.5% (w/v) Nonidet P40, 
Complete Protease Inhibitor Cocktail (Roche, Basel, 
Switzerland), PhosSTOP Phosphatase Inhibitor Cocktail 
(Roche)]. Cells were vortexed with periodic cooling on 
ice for 1 h and then centrifuged at 13,000 rpm for 10 
min at 4°C. Cell extracts were resuspended in a loading 
buffer and stored at -80°C until analysis by Western 
blotting. Proteins were separated by electrophoresis 
on the Mini-protean TGX gel (Bio-Rad, Hercules, 
CA) and transferred to Immobilon-P polyvinylidene 
difluoride (PVDF) membranes (Millipore, Bedford, 
MA). Antibodies against Vimentin (V9), K-Ras (F234), 
IQGAP1 (H109), p68 RNA Helicase (H144) or β-actin 
(C4) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Antibodies against Zeb1 (3396), 
phospho-Akt (Ser473) (4060), Akt (Pan) (4691), 
phospho-Erk1/2 (Thr202/Tyr204) (4370), Erk1/2 
(4695), phospho-Stat3 (Tyr705) (9145), Stat3 (9132) 
and rabbit IgG, as well as mouse IgG conjugated with 
horseradish peroxidase (HRP) were purchased from 
Cell Signaling Technology (Danvers, MA). Antibody 
against E-cadherin (610182) was purchased from BD 
Biosciences (San Jose, CA).
Establishment of stable K-Ras silenced NSCLC 
cells
K-Ras shRNA lentiviral particles (sc-35731-v) 
and control shRNA lentiviral particles (sc-108080) 
were purchased from Santa Cruz Biotechnology. To 
establish stable knockdown cell lines, NSCLC cells were 
transfected with shRNA lentiviral particles, and cultured 
in the presence of 2 μg/mL puromycin. Cells were 
characterized for the K-Ras expression level by western 
blot assay.
Pull down assay with CaM-sepharose
The pull-down assay was performed using CaM-
Sepharose Beads (BioVision, Milpitas, CA). Cells were 
lysed with pull-down buffer [50 mM Tris-HCL (pH7.5), 
150 mM NaCl, 1 % Triton X-100, 1 mM dithiothreitol 
(DTT), Complete Protease Inhibitor Cocktail and 
PhosSTOP Phosphatase Inhibitor Cocktail]. Clear 
lysate was collected after centrifugation at 13,000 rpm 
for 10 min at 4 °C. CaM-sepharose beads (Biovision, 
Milpitas, CA) and Plain beads (Sepharose 6 fast flow, GE 
healthcare, Uppsala, Sweden) were equilibrated with pull-
down buffer. CaM-sepharose beads were pretreated with 
CBP501 or other compounds for 1 h at 4 °C. The clarified 
cell lysates were incubated with CaM beads or Plain beads 
in combination with CBP501 or other compounds for 2 h 
at 4 °C in the presence of 0.1 mM CaCl2. After incubation, 
beads were washed thrice with pull-down buffer. The 
proteins bound to the beads were eluted by boiling for 5 
min in 5 × SDS-PAGE loading buffer. Then the samples 
were analyzed by Western blotting.
Statistical analysis
Data were analyzed using the t test (Student’s t 
test or Welch’s t test). All experiments were performed 
in triplicate. Data are expressed as the mean ± standard 
deviation (SD). A P value of < 0.05 or < 0.005 was 
considered significant.
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